Consensus Rating1
Buy
Highest Price Target1
$37.00
Lowest Price Target1
$27.00
Consensus Price Target1
$32.50

Enliven Therapeutics (NASDAQ:ELVN) Stock, Analyst Ratings, Price Targets, Forecasts

Enliven Therapeutics Inc has a consensus price target of $32.5 based on the ratings of 5 analysts. The high is $37 issued by HC Wainwright & Co. on September 9, 2024. The low is $27 issued by Jefferies on March 29, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Baird, and Mizuho on September 9, 2024, June 11, 2024, and April 9, 2024, respectively. With an average price target of $34.33 between HC Wainwright & Co., Baird, and Mizuho, there's an implied 48.82% upside for Enliven Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Apr
1
Jun
0
0
0
0
Sep
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Baird
Mizuho
Jefferies

1calculated from analyst ratings

Analyst Ratings for Enliven Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Enliven Therapeutics (ELVN) stock?

A

The latest price target for Enliven Therapeutics (NASDAQ:ELVN) was reported by HC Wainwright & Co. on September 9, 2024. The analyst firm set a price target for $37.00 expecting ELVN to rise to within 12 months (a possible 60.38% upside). 3 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Enliven Therapeutics (ELVN)?

A

The latest analyst rating for Enliven Therapeutics (NASDAQ:ELVN) was provided by HC Wainwright & Co., and Enliven Therapeutics initiated their buy rating.

Q

When was the last upgrade for Enliven Therapeutics (ELVN)?

A

There is no last upgrade for Enliven Therapeutics

Q

When was the last downgrade for Enliven Therapeutics (ELVN)?

A

There is no last downgrade for Enliven Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Enliven Therapeutics (ELVN)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enliven Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enliven Therapeutics was filed on September 9, 2024 so you should expect the next rating to be made available sometime around September 9, 2025.

Q

Is the Analyst Rating Enliven Therapeutics (ELVN) correct?

A

While ratings are subjective and will change, the latest Enliven Therapeutics (ELVN) rating was a initiated with a price target of $0.00 to $37.00. The current price Enliven Therapeutics (ELVN) is trading at is $23.07, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch